ADMA Biologics (NASDAQ:ADMA) Shares Down 5.5% – Here’s Why

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded down 5.5% during trading on Tuesday . The stock traded as low as $8.66 and last traded at $8.6350. Approximately 452,434 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 4,254,918 shares. The stock had previously closed at $9.14.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price for the company. Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research note on Monday. Finally, Mizuho reduced their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Three investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, ADMA Biologics currently has a consensus rating of “Moderate Buy” and an average target price of $18.67.

ADMA Biologics Stock Up 3.4%

The stock has a 50 day moving average of $9.21 and a 200-day moving average of $9.89. The firm has a market capitalization of $1.99 billion, a P/E ratio of 12.71 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.16. The firm had revenue of $124.39 million during the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The company’s quarterly revenue was up 2.0% on a year-over-year basis. During the same quarter last year, the business earned $0.14 earnings per share. Research analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ADMA. Western Wealth Management LLC bought a new stake in ADMA Biologics during the 1st quarter valued at $31,000. Integrated Wealth Concepts LLC bought a new position in shares of ADMA Biologics in the second quarter worth $42,000. Quantbot Technologies LP purchased a new position in shares of ADMA Biologics in the second quarter valued at $51,000. Larson Financial Group LLC grew its position in shares of ADMA Biologics by 745.1% in the fourth quarter. Larson Financial Group LLC now owns 3,262 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,876 shares in the last quarter. Finally, Nykredit A S purchased a new position in shares of ADMA Biologics in the second quarter valued at $59,000. 75.68% of the stock is owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.